RxDoctor Payments Data

Mary Davidian, MD

Ophthalmology · New Windsor, NYNPI 1780683052

Payments from drug & device makers

$31,821in general payments, 2019–2025

Across 458 payments — averaging $69.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dompe US, Inc.$15K
  • Biotissue Holdings Inc.$7K
  • AbbVie$2K
  • Alcon$2K
  • Sun Pharmaceutical Industries Inc.$795
  • Sight Sciences, Inc.$726
  • plus $6K from 29 others

What the payments were for

  • Consulting fees$4,55014%
  • Speaking & faculty fees$12,79340%
  • Travel & lodging$1,2394%
  • Food & beverage$13,08341%
  • Education$1370%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,821 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$318,597
Medicare patients
694
Services billed
2,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj16$562,875
RestasisCyclosporine276$400,075
XiidraLifitegrast80$148,421
MieboPerfluorohexyloctane/Pf59$55,718
TyrvayaVarenicline Tartrate56$53,823
Cyclosporine83$44,967
XdemvyLotilaner21$38,682
Loteprednol Etabonate113$28,151
Prednisolone Acetate385$27,320
LumiganBimatoprost37$23,363
BromsiteBromfenac Sodium60$15,815
ValacyclovirValacyclovir Hcl138$14,699
Lotemax SmLoteprednol Etabonate50$14,309
ZirganGanciclovir24$13,471
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol42$11,503

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$14,587$562,87516 claims
AbbVieRestasis, Lumigan, Combigan$1,610$429,058325 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Zirgan$481$217,610163 claims
Oyster Point Pharma, Inc.Tyrvaya$551$53,82356 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm$307$42,460163 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$244$38,68221 claims
Sun Pharmaceutical Industries Inc.Bromsite$795$15,81560 claims
AlconSimbrinza$1,533$9,00817 claims
Eyevance Pharmaceuticals LLCFlarex$97$3,50322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in New Windsor

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →